Satellos Bioscience Inc.

Satellos Bioscience Inc. (NASDAQ:MSLE) is a publicly traded company in the Life Sciences sector. Wiseek monitors MSLE SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

• Satellos Reports Q1 2026 Financials, $51.9M Net Proceeds from Equity Offering Extends Runway Through 2027, and Advances Phase 2 DMD Trials (2026-05-15)
• Satellos Bioscience Secures $57.2M in Premium-Priced Public Offering, Advances Clinical Programs (2026-03-27)
• Satellos Bioscience Reports 2025 Results, Confirms Strong Cash Runway & Advances Phase 2 DMD Trials (2026-03-27)
• Satellos Reports Positive Interim Clinical Data for SAT-3247 in DMD and Preclinical Data in FSHD (2026-03-10)
• Satellos Bioscience to Present Key Clinical and Preclinical Data at 2026 MDA Conference (2026-02-24)

Insider Transactions

MSLE files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.